PROCEPT BioRobotics Corpo... (PRCT)
PROCEPT BioRobotics Corporation (PRCT) Stock Price, Analysis & Data
| Bid | 13.9 |
| Market Cap | 1.21B |
| Revenue (ttm) | 337.34M |
| Net Income (ttm) | -109.75M |
| Beta | 0.89 |
| EPS (ttm) | -1.95 |
| PE Ratio (ttm) | n/a |
| Forward PE | -18.43 |
| P/B (ttm) | 3.58 |
| P/S (ttm) | 3.61 |
| Earnings Date | Nov 4, 2026 |
| Ask | 22.04 |
| Volume | 1,118,431 |
| Avg. Volume (20D) | 1,708,754 |
| Open | 22.45 |
| Previous Close | 22.89 |
| Day's Range | 21.18 - 22.68 |
| 52-Week Range | 16.66 - 42.70 |
| Analyst | Hold |
| Price Target | 21 (-1.18%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided rob...
Financial Performance
In 2025, PROCEPT BioRobotics's revenue was 308.05M, an increase of 37.22% compared to the previous year's 224.5M. Earnings were -95.57M, an increase of 4.55%.
Financial StatementsAnalyst Forecast
According to 11 analyst ratings, the average rating for PRCT stock is "Hold". The 12-month stock price forecast is 21, which is downside of 1.18% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
